Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders??? Equity (Unaudited)

v3.19.1
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
Common Stock
Additional Paid-In Capital
Other Comprehensive Income (Loss)
Deficit Accumulated During The Research And Development Stage
Total
Beginning Balance, Shares at Dec. 31, 2017 26,519,394        
Beginning Balance, Amount at Dec. 31, 2017 $ 26,519 $ 65,774,870 $ (129,343) $ (55,714,178) $ 9,957,868
Common stock issued for cash, net, Shares 3,500,000        
Common stock issued for cash, net, Amount $ 3,500 7,792,500 7,796,000
Common stock issued for cashless exercise of warrants, Shares 11,399        
Common stock issued for cashless exercise of warrants, Amount $ 12 (12)
Employee stock options granted for services 895,226 895,226
Warrants granted for services 2,199 2,199
Other comprehensive income 14,947 14,947
Net loss for the year (4,652,421) (4,652,421)
Ending Balance, Shares at Mar. 31, 2018 30,030,793        
Ending Balance, Amount at Mar. 31, 2018 $ 30,031 74,464,783 (114,396) (60,366,599) 14,013,819
Beginning Balance, Shares at Dec. 31, 2018 35,335,378        
Beginning Balance, Amount at Dec. 31, 2018 $ 35,335 85,604,271 223,651 (73,722,801) 12,140,456
Common stock issued for cash, net, Shares 2,478,613        
Common stock issued for cash, net, Amount $ 2,479 6,658,192 6,660,671
Employee stock options granted for services 338,331 338,331
Warrants granted for services 2,127 2,127
Other comprehensive income (24,054) (24,054)
Modification of financing warrants 196,957 196,957
Net loss for the year (4,203,773) (4,203,773)
Ending Balance, Shares at Mar. 31, 2019 37,813,991        
Ending Balance, Amount at Mar. 31, 2019 $ 37,814 $ 92,799,878 $ 199,597 $ (77,926,574) $ 15,110,715